|  | Conditions & Treatments | Hepatitis

Hepatitis B Contraindications: Understanding Risks & Limitations

In hepatitis B management, contraindications are specific clinical scenarios where a treatment, medication, or intervention may be unsafe or inappropriate. Understanding these helps guide individualized therapy.

Key Contraindications & Precautions by Therapy

Nucleos(t)ide Analogues (NAs)

DrugContraindications / Major Precautions
Tenofovir disoproxil fumarate (TDF)Severe renal impairment (CrCl <30 mL/min) without dose adjustment; decompensated cirrhosis (Child-Pugh B/C) requires monitoring; bone disease/osteoporosis risk
Tenofovir alafenamide (TAF)Severe renal impairment (CrCl <15 mL/min) not studied; caution with severe hepatic impairment
EntecavirDose adjustment required for CrCl <50 mL/min; limited data in decompensated cirrhosis
Lamivudine / TelbivudineRenal dose adjustment needed; high resistance rates limit use; telbivudine contraindicated with peripheral neuropathy
AdefovirNephrotoxicity risk; dose adjust for CrCl <50 mL/min; avoid with other nephrotoxins

Interferon-Based Therapy

  • Absolute contraindications: Decompensated cirrhosis (Child-Pugh B/C), autoimmune hepatitis, severe psychiatric illness (depression, psychosis), uncontrolled seizures, pregnancy, solid organ transplant (rejection risk), severe cardiac disease
  • Relative cautions: Thyroid disease, cytopenias, retinal disease, COPD, age >60, comorbid substance use

Special Populations

Pregnancy & Breastfeeding

  • Preferred: TDF, TAF, telbivudine (Category B)
  • Avoid: Interferons (abortifacient), adefovir (Category C), entecavir (Category C)
  • Lamivudine: safe but high resistance risk if used alone

Renal Impairment

  • All NAs require dose adjustment except TAF (down to CrCl 15 mL/min)
  • TDF avoid if CrCl <30 mL/min without adjustment

Decompensated Cirrhosis

  • TDF or TAF preferred; entecavir alternative
  • Interferons contraindicated
  • Close monitoring for lactic acidosis, renal function, hepatic decompensation

Coinfections (HIV, HCV, HDV)

  • HIV/HBV: Must use dual-active ART (TDF/TAF + 3TC/FTC) to prevent HIV resistance
  • HCV/HBV: Treat HCV first; monitor HBV reactivation during DAA therapy
  • HDV: Pegylated interferon only approved therapy; NAs alone insufficient

Clinical Decision Framework

  1. Assess liver disease stage (fibrosis, Child-Pugh)
  2. Evaluate renal function (eGFR)
  3. Screen for comorbidities (psychiatric, autoimmune, cardiac, bone)
  4. Determine pregnancy status/plans
  5. Check for drug interactions
  6. Select agent with highest barrier to resistance and best safety profile for the individual

Always consult a hepatologist or infectious disease specialist for personalized hepatitis B treatment decisions.

Hepatitis - Related Articles